Singapore markets closed
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
63,950.38 +192.05 (+0.30%) CMC Crypto 200
1,386.08 +73.45 (+5.60%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 139.83 |
| Open | 140.90 |
| Bid | 140.61 x 200 |
| Ask | 140.79 x 200 |
| Day's range | 139.24 - 141.69 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 909,878 |
| Market cap | 14.161B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 38.13 |
| EPS (TTM) | 3.69 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 157.50 |
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
Simply Wall St.Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
© 2024 Yahoo. All rights reserved.